Amgen June 15th Short Interest Update

Amgen (NASDAQ:AMGN) encountered a drop of 1.5% or -110,785 shares in the short positions. The number dropped from 7,308,083 on May 31,2016 to 7,197,298 on June 15,2016. The final interest is 1% of the floated stock. The days to cover figure of 3 can be arrived using the average daily exchange of 2,221,116 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Amgen (NASDAQ:AMGN): The stock opened at $147.20 on Friday but the bulls could not build on the opening and the stock topped out at $149.30 for the day. The stock traded down to $146.03 during the day, due to lack of any buying support eventually closed down at $146.45 with a loss of -3.82% for the day. The stock had closed at $152.27 on the previous day. The total traded volume was 4,919,244 shares.

The company shares have dropped -3.40% from its 1 Year high price. On Jul 31, 2015, the shares registered one year high at $181.81 and the one year low was seen on Sep 28, 2015. The 50-Day Moving Average price is $153.73 and the 200 Day Moving Average price is recorded at $153.30.

Amgen (NASDAQ:AMGN) has tumbled 2.12% during the past week and has dropped 6.57% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 0.49%. Amgen (NASDAQ:AMGN) has underperformed the index by 3.74% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering, developing, manufacturing and delivering human therapeutics. The Companys sales and marketing forces are located in the United States and Europe. In the United States, it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising, as well as through the Internet. Outside the United States, the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Companys products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim), Enbrel (etanercept), XGEVA/Prolia (denosumab), ESAs (erythropoiesis-stimulating agents), Sensipar/Mimpara (cinacalcet), Kyprolis and Evolocumab, among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.